Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

Abstract

Charcot-Marie-Tooth (CMT) disease is the most common inherited neuromuscular disorder, affecting at least 1 in 2500 individuals. CMT refers to a heterogeneous group of inherited neuropathies from both phenotypic and genetic points of view. Over the last decades, there have been important advances not only in the identification of causative genes but also in understanding the molecular basis for many forms of CMT. In fact, to date, around 100 genes have been related to CMT disease, thanks to next generation sequencing techniques, and they have been proven to affect either the myelin or axon of peripheral nerves. Moreover, its genetic diagnosis has remarkedly improved, although there are still difficulties when it comes to treatment. In this review, we explore in depth the eight most prevalent genes associated with CMT: GDAP1, GJB1, HINT1, MFN2, MPZ, PMP22, SH3TC2, and SORD. We also address the disrupted cellular processes and pathophysiological mechanisms involved in the disease. A better understanding of the pathogenic mechanisms responsible for each type of CMT would be essential to identifying molecular targets and therapeutic strategies.

Keywords

Charcot-Marie-Tooth disease / genetic diagnosis / genetic neuropathies / inherited peripheral neuropathies / pathogenic pathways

References

[1] CharcotJM. Sur une forme particulière d’atrophie musculaire progressive souvent familiale débutant par les pieds et les jambes et atteignant plus tard les mains. Paris: Félix Alcan; 1886. pp. 97-138.

[2] ToothHH. The peroneal type of progressive muscular atrophy: a thesis for the degree of M.D. in the university of cambridge - digital collections - national library of medicine. Available from: https://collections.nlm.nih.gov/catalog/nlm:nlmuid-100899256-bk [Last accessed on 13 June 2022]

[3] PisciottaC.Neuropathy.Handb Clin Neurol2018;148:653-665

[4] ReillyMM,LauráM.Charcot-Marie-Tooth disease.J Peripher Nerv Syst2011;16:1-14

[5] BarretoLC,NunesPS.Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review.Neuroepidemiology2016;46:157-65

[6] CombarrosO,PoloJM.Prevalence of hereditary motor and sensory neuropathy in Cantabria.Acta Neurol Scand1987;75:9-12

[7] BirdTD. Charcot-Marie-Tooth (CMT) hereditary neuropathy overview. 1998 Sep 28 [updated 2021 Sep 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®[Internet]. Seattle, WA: University of Washington, 1993-2022.

[8] HardingAE.The clinical features of hereditary motor and sensory neuropathy types I and II.Brain1980;103:259-80

[9] WerheidF,ZwerenzE.Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene?.Brain Behav2016;6:e00451 PMCID:PMC4782242

[10] AnzaloneCL,OlundAP.Cochlear implantation in Charcot-Marie-Tooth disease: case report and review of the literature.Case Rep Med2018;2018:1760978 PMCID:PMC5892247

[11] LeratJ,Beauvais-DzuganH.A novel pathogenic variant of NEFL responsible for deafness associated with peripheral neuropathy discovered through next-generation sequencing and review of the literature.J Peripher Nerv Syst2019;24:139-44

[12] Jani-AcsadiA,PierzK.Pediatric Charcot-Marie-Tooth disease.Pediatr Clin N Am2015;62:767-86

[13] SaportaAS,MillerLJ,SiskindCE.Charcot-Marie-Tooth disease subtypes and genetic testing strategies.Ann Neurol2011;69:22-33 PMCID:PMC3058597

[14] RossorAM,HouldenH.Clinical implications of genetic advances in Charcot-Marie-Tooth disease.Nat Rev Neurol2013;9:562-71

[15] RaeymaekersP,NelisE.Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a).Neuromuscul Disord1991;1:93-7

[16] LupskiJR,SlaugenhauptS.DNA duplication associated with Charcot-Marie-Tooth disease type 1A.Cell1991;66:219-32

[17] Gonzaga-JaureguiC,GambinT.Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy .Cell Rep2015;12:1169-83

[18] BlairIP,GordonMJ.Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin.Am J Hum Genet1996;58:472-6 PMCID:PMC1914557

[19] OuvrierR.What can we learn from the history of Charcot-Marie-Tooth disease?.Dev Med Child Neurol2010;52:405-6

[20] MagyL,LeMasson G,TazirM.Updating the classification of inherited neuropathies: Results of an international survey.Neurology2018;90:e870-6

[21] MathisS,TazirM.Charcot-Marie-Tooth diseases: an update and some new proposals for the classification.J Med Genet2015;52:681-90

[22] TimmermanV,ZüchnerS.Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success.Genes2014;5:13-32 PMCID:PMC3978509

[23] HøyerH,BuskØL.Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next-generation sequencing.Biomed Res Int2014;2014:210401

[24] JuárezP.Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy.Neural Plast2012;2012:171636 PMCID:PMC3382403

[25] CohenE,RivierF.The 2022 version of the gene table of neuromuscular disorders (nuclear genome).Neuromuscul Disord2021;31:1313-57

[26] RossorAM,ReillyMM.A practical approach to the genetic neuropathies.Pract Neurol2015;15:187-98

[27] MillerLJ,SottileSL,FeelySM.Strategy for genetic testing in Charcot-Marie-disease.Acta Myol2011;30:109-16 PMCID:PMC3235845

[28] CorteseA,PolkeJM.Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease.Neurology2020;94:e51-61

[29] YuberoD,PijuanJ.The increasing impact of translational research in the molecular diagnostics of neuromuscular diseases.Int J Mol Sci2021;22:4274 PMCID:PMC8074304

[30] RichardsS,BaleS.ACMG Laboratory Quality Assurance CommitteeStandards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med2015;17:405-24 PMCID:PMC4544753

[31] YoungP,StögbauerF.Treatment for Charcot-Marie-Tooth disease.Cochrane Database Syst Rev2008;1:CD006052 PMCID:PMC6718225

[32] SackleyC,Turner-stokesL.Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database of Systematic Reviews.Cochrane Database Syst Rev2009;8:CD003908

[33] GuillebastreB,RougierPR.Assessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth disease.Am J Phys Med Rehabil2011;90:619-27

[34] Jani-AcsadiA,ShyME.Charcot-Marie-Tooth neuropathies: diagnosis and management.Semin Neurol2008;28:185-94

[35] BurnsJ,OuvrierR.Effective orthotic therapy for the painful cavus foot: a randomized controlled trial.J Am Podiatr Med Assoc2006;96:205-11

[36] PiscosquitoG,SchenoneA.CMT-TRIAAL & CMT-TRAUK GroupIs overwork weakness relevant in Charcot-Marie-Tooth disease?.J Neurol Neurosurg Psychiatry2014;85:1354-8

[37] BealsTC.Charcot-Marie-Tooth disease and the cavovarus foot.Foot Ankle Clin2008;13:259-74

[38] ShyME.Therapeutic strategies for the inherited neuropathies.Neuromol Med2006;8:255-78

[39] HerrmannDN.Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.Neurotherapeutics2008;5:507-15 PMCID:PMC4514696

[40] zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.Ann Neurol2007;61:61-72

[41] SahenkZ,McCrackenBS.NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.Neurology2005;65:681-9

[42] PassageE,Noack-FraissignesP.Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.Nat Med2004;10:396-401

[43] SinghS.From exotic spice to modern drug?.Cell2007;130:765-8

[44] GessB,DeJonghe P,PareysonD.Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.Cochrane Database Syst Rev2015;12:CD011952 PMCID:PMC6823270

[45] SeredaMW,SuterU,NaveKA.Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).Nat Med2003;9:1533-7

[46] AttarianS,BrannaganTH.A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.Orphanet J Rare Dis2021;16:433 PMCID:PMC8520617

[47] d'YdewalleC,ChihebDM.HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.Nat Med2011;17:968-74

[48] AdalbertR,AntoniouC.Novel HDAC6 Inhibitors increase tubulin acetylation and rescue axonal transport of mitochondria in a model of Charcot-Marie-Tooth type 2F.ACS Chem Neurosci2020;11:258-67

[49] PicciC,CostaCJ.HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.Exp Neurol2020;328:113281

[50] PisciottaC,PareysonD.Challenges in treating Charcot-Marie-Tooth disease and related neuropathies: current management and future perspectives.Brain Sci2021;11:1447 PMCID:PMC8615778

[51] RossaertE.HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT.Brain Res2020;1733:146692

[52] Nuevo-TapiolesC,Sánchez-GarridoB.Effective therapeutic strategies in a preclinical mouse model of Charcot-Marie-Tooth disease.Hum Mol Genet2021;30:2441-55 PMCID:PMC8643506

[53] KagiavaA,RichterJ.AAV9-mediated schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.Gene Ther2021;28:659-75 PMCID:PMC8599011

[54] MarcoA,PedrolaL,MarínI.Evolutionary and structural analyses of GDAP1, involved in Charcot-Marie-Tooth disease, characterize a novel class of glutathione transferase-related genes.Mol Biol Evol2004;21:176-87

[55] HuberN,WagnerKM.Glutathione-conjugating and membrane-remodeling activity of GDAP1 relies on amphipathic C-terminal domain.Sci Rep2016;6:36930 PMCID:PMC5107993

[56] ChenCX,DongHL,BaiG.Identification and functional characterization of novel GDAP1 variants in Chinese patients with Charcot-Marie-Tooth disease.Ann Clin Transl Neurol2020;7:2381-92 PMCID:PMC7732252

[57] NiemannA,LaPadula V,SuterU.Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease.J Cell Biol2005;170:1067-78 PMCID:PMC2171517

[58] PedrolaL,Valdés-SánchezT.Cell expression of GDAP1 in the nervous system and pathogenesis of Charcot-Marie-Tooth type 4A disease.J Cell Mol Med2008;12:679-89 PMCID:PMC2570022

[59] BiniędaK,KolakowskiD.Mutations in.GDAP12018;22:914 PMCID:PMC7831947

[60] AzzedineH,EnteD.Variability of disease progression in a family with autosomal recessive CMT associated with a S194X and new R310Q mutation in the GDAP1 gene.Neuromuscul Disord2003;13:341-6

[61] ManganelliF,NolanoM.A novel autosomal dominant GDAP1 mutation in an Italian CMT2 family.J Peripher Nerv Syst2012;17:351-5

[62] CantareroL,Civera-TregónA.Mitochondria-lysosome membrane contacts are defective in GDAP1-related Charcot-Marie-Tooth disease.Hum Mol Genet2021;29:3589-605 PMCID:PMC7823109

[63] SevillaT,ChumillasMJ.Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene.Brain2003;126:2023-33

[64] NiemannA,RueggM.GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance.Neurobiol Dis2009;36:509-20

[65] NoackR,AlbrechtP.Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential.Hum Mol Genet2012;21:150-62

[66] Pla-MartínD,EstelaA.Silencing of the Charcot-Marie-Tooth disease-associated gene GDAP1 induces abnormal mitochondrial distribution and affects Ca2+ homeostasis by reducing store-operated Ca2+ entry.Neurobiol Dis2013;55:140-51

[67] PijuanJ,Natera-deBenito D.Mitochondrial dynamics and mitocondria-lysosome contacts in neurogenetic diseases.Front Neurosci2022;16:784880 PMCID:PMC8844575

[68] CassereauJ,GueguenN.Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K).Neurogenetics2009;10:145-50

[69] García-SobrinoT,PalauF.Phenotypical features of a new dominant GDAP1 pathogenic variant (p.R226del) in axonal Charcot-Marie-Tooth disease.Neuromuscul Disord2017;27:667-72

[70] González-SánchezP,Martínez-ValeroP.CMT-linked loss-of-function mutations in GDAP1 impair store-operated Ca²⁺ entry-stimulated respiration.Sci Rep2017;7:42993 PMCID:PMC5318958

[71] CassereauJ,CodronP.Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K.Exp Neurol2020;323:113069

[72] KleopaKA,SchererSS.How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease?.Brain Res2012;1487:198-205 PMCID:PMC3488165

[73] LatourP,OllagnonE.SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations.J Peripher Nerv Syst2006;11:148-55

[74] WangY.A Review of X-linked Charcot-Marie-Tooth Disease.J Child Neurol2016;31:761-72

[75] AbramsCK.GJB1 disorders: Charcot-Marie-Tooth Neuropathy (CMT1X) and central nervous system phenotypes. 1998 Jun 18 [updated 2020 Feb 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, 1993-2022.

[76] SiskindCE,OvensR,ReillyMM.Phenotype expression in women with CMT1X.J Peripher Nerv Syst2011;16:102-7

[77] DubourgO,BiroukN.Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease.Brain2001;124:1958-67

[78] TsaiPC,LiuAB.Mutational analysis of the 5' non-coding region of GJB1 in a Taiwanese cohort with Charcot-Marie-Tooth neuropathy.J Neurol Sci2013;332:51-5

[79] HahnAF,BoltonCF,VallatJM.Pathological findings in the x-linked form of Charcot-Marie-Tooth disease: a morphometric and ultrastructural analysis.Acta Neuropathol2001;101:129-39

[80] AbramsCK.GJB1-associated X-linked Charcot-Marie-Tooth disease, a disorder affecting the central and peripheral nervous systems.Cell Tissue Res2015;360:659-73

[81] AltevogtBM,PostmaFR,PaulDL.Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems.J Neurosci2002;22:6458-70 PMCID:PMC6758161

[82] Balice-GordonRJ,SchererSS.Functional gap junctions in the schwann cell myelin sheath.J Cell Biol1998;142:1095-104 PMCID:PMC2132877

[83] ChandrossKJ,CohenRI.Altered connexin expression after peripheral nerve injury.Mol Cell Neurosci1996;7:501-18

[84] SchererS,XuY,FischbeckK.Connexin32 is a myelin-related protein in the PNS and CNS.J Neurosci1995;15:8281-94 PMCID:PMC6577923

[85] SutorB,TeubnerB,WilleckeK.Myelination defects and neuronal hyperexcitability in the neocortex of connexin 32-deficient mice.Cereb Cortex2000;10:684-97

[86] BeauvaisK,LatourP.Clinical, electrophysiological and molecular genetic studies in a family with X-linked dominant Charcot-Marie-Tooth neuropathy presenting a novel mutation in GJB1 Promoter and a rare polymorphism in LITAF/SIMPLE.Neuromuscul Disord2006;16:14-8

[87] HouldenH,CockerellC.Connexin 32 promoter P2 mutations: a mechanism of peripheral nerve dysfunction.Ann Neurol2004;56:730-4

[88] Gonzaga-JaureguiC,TowneCF,LupskiJR.GJB1/Connexin 32 whole gene deletions in patients with X-linked Charcot-Marie-Tooth disease.Neurogenetics2010;11:465-70 PMCID:PMC4222676

[89] BicegoM,HernandezVH.Selective defects in channel permeability associated with Cx32 mutations causing X-linked Charcot-Marie-Tooth disease.Neurobiol Dis2006;21:607-17

[90] AbramsCK,MahmoudR,BargielloTA.Functional requirement for a highly conserved charged residue at position 75 in the gap junction protein connexin 32.J Biol Chem2013;288:3609-19 PMCID:PMC3561579

[91] JengLJ,MessingA,SchererSS.The effects of a dominant connexin32 mutant in myelinating Schwann cells.Mol Cell Neurosci2006;32:283-98

[92] ZimońM,Almeida-SouzaL.Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia.Nat Genet2012;44:1080-3

[93] PeetersK,TournevI.Axonal neuropathy with neuromyotonia: there is a HINT.Brain2017;140:868-77 PMCID:PMC5382946

[94] RauchenzaunerM,HechtM,Witsch-BaumgartnerM.A Novel variant in the HINT1 gene in a girl with autosomal recessive axonal neuropathy with neuromyotonia: thorough neurological examination gives the clue.Neuropediatrics2016;47:119-22

[95] CaetanoJS,BaetsJ.Autosomal recessive axonal neuropathy with neuromyotonia: a rare entity.Pediatr Neurol2014;50:104-7

[96] LaššuthováP,KrůtováM.Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy among Czech patients and neuromyotonia is rather an underdiagnosed symptom.Neurogenetics2015;16:43-54

[97] KontogeorgiouZ,KartanouC.HINT1-related neuropathy in Greek patients with Charcot-Marie-Tooth disease.J Peripher Nerv Syst2021;26:444-8

[98] ChouTF,WagnerCR.Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity.Biochemistry2007;46:13074-9

[99] OuvrierR,MorganG,ConchinT.Hereditary motor and sensory neuropathy of neuronal type with onset in early childhood.J Neurol Sci1981;51:181-97

[100] LeeM,ChungHK.Cerebral white matter abnormalities in patients with charcot-marie-tooth disease.Ann Neurol2017;81:147-51

[101] LarreaD,GonnelliA.MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics.Hum Mol Genet2019;28:1782-800

[102] PipisM,PolkeJM.Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study.Brain2020;143:3589-602 PMCID:PMC7805791

[103] BombelliF,DubourgO.Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features.JAMA Neurol2014;71:1036-42

[104] FeelySM,SiskindCE.MFN2 mutations cause severe phenotypes in most patients with CMT2A.Neurology2011;76:1690-6 PMCID:PMC3100135

[105] YouleRJ.Mitochondrial fission, fusion, and stress.Science2012;337:1062-5 PMCID:PMC4762028

[106] Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria.Nature2008;456:605-10

[107] KoshibaT,KaiserJT,McCafferyJM.Structural basis of mitochondrial tethering by mitofusin complexes.Science2004;305:858-62

[108] ChenH.Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases.Hum Mol Genet2009;18:R169-76 PMCID:PMC2758711

[109] LealNS,PinhoCM.Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide production.J Cell Mol Med2016;20:1686-95 PMCID:PMC4988279

[110] FiladiR,TuracchioG,PozzanT.Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling.Proc Natl Acad Sci USA2015;112:E2174-81 PMCID:PMC4418914

[111] MerkwirthC.Mitofusin 2 builds a bridge between ER and mitochondria.Cell2008;135:1165-7

[112] VielhaberS,PeevaV.Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion.Acta Neuropathol2013;125:245-56

[113] AmiottEA,SotoJ.Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations.Exp Neurol2008;211:115-27 PMCID:PMC2409111

[114] LoiseauD,VernyC.Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease.Ann Neurol2007;61:315-23

[115] ChandhokG,NeumannB.Structure, function, and regulation of mitofusin-2 in health and disease.Biol Rev Camb Philos Soc2018;93:933-49 PMCID:PMC6446723

[116] WestermannB.Mitochondrial fusion and fission in cell life and death.Nat Rev Mol Cell Biol2010;11:872-84

[117] ElFissi N,AouaneA.Mitofusin gain and loss of function drive pathogenesis in.Drosophila2018;19:e45241 PMCID:PMC6073211

[118] TomaselliPJ,CorteseA,RossorAM.Severe cognitive impairment in a patient with CMT2A.J Peripher Nerv Syst2018;23:147-8

[119] FiladiR,PizzoP.Mitofusin 2: from functions to disease.Cell Death Dis2018;9:330 PMCID:PMC5832425

[120] OtaniY,CuiJ,BabaH.Upregulation of large myelin protein zero leads to Charcot-Marie-Tooth disease-like neuropathy in mice.Commun Biol2020;3:121 PMCID:PMC7070019

[121] JerathNU.Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future treatment strategies.Biochim Biophys Acta2015;1852:667-78

[122] ShyME,KrajewskiK.Phenotypic clustering in MPZ mutations.Brain2004;127:371-84

[123] RaasakkaA,KowalJ.Molecular structure and function of myelin protein P0 in membrane stacking.Sci Rep2019;9:642 PMCID:PMC6345808

[124] LuoX,InouyeH.Cytoplasmic domain of human myelin protein zero likely folded as beta-structure in compact myelin.Biophys J2007;92:1585-97 PMCID:PMC1796833

[125] BaiY,BrennanKM.Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B.Ann Clin Transl Neurol2018;5:445-55 PMCID:PMC5899917

[126] ChancePF,LeppigKA.DNA deletion associated with hereditary neuropathy with liability to pressure palsies.Cell1993;72:143-51

[127] BortS,TimmermanV.Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies.Hum Genet1997;99:746-54

[128] BraathenGJ,LobatoA,RussellMB.Genetic epidemiology of Charcot-Marie-Tooth in the general population.Eur J Neurol2011;18:39-48

[129] KaradimaG,KoutsisG,PanasM.Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patients.Clin Genet2011;80:497-9

[130] Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.Orphanet J Rare Dis2014;9:38 PMCID:PMC3994927

[131] BoutaryS,AdamsD.Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future.Transl Res2021;227:100-11

[132] LiJ,MartynC,GuoJ.The PMP22 gene and its related diseases.Mol Neurobiol2013;47:673-98 PMCID:PMC3594637

[133] YuanJH,OkamotoY.Clinical and mutational spectrum of Japanese patients with recessive variants in SH3TC2.J Hum Genet2018;63:281-7

[134] Pérez-GarriguesH,VílchezJJ,PalauF.Vestibular impairment in Charcot-Marie-Tooth disease type 4C.J Neurol Neurosurg Psychiatry2014;85:824-7

[135] ClaramuntR,LupoV.The p.R1109X mutation in SH3TC2 gene is predominant in Spanish Gypsies with Charcot-Marie-Tooth disease type 4.Clin Genet2007;71:343-9

[136] LaššuthováP,VondráčekP.High frequency of SH3TC2 mutations in Czech HMSN I patients.Clin Genet2011;80:334-45

[137] AzzedineH.SH3TC2-related hereditary motor and sensory neuropathy. 2008 Mar 31 [updated 2021 Mar 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, 1993-2022.

[138] LupoV,Martínez-RubioD.Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway.Hum Mol Genet2009;18:4603-14

[139] GouttenoireEA,CalpenaE.Sh3tc2 deficiency affects neuregulin-1/ErbB signaling.Glia2013;61:1041-51

[140] CorteseA,RebeloAP.Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes.Nat Genet 2020;52:473-81

[141] DongHL,LiuGL,WuZY.Biallelic SORD pathogenic variants cause Chinese patients with distal hereditary motor neuropathy.NPJ Genom Med2021;6:1 PMCID:PMC7782788

[142] LiuX,YilihamuM,FanD.Clinical and genetic features of biallelic mutations in.SORD2021;12:733926 PMCID:PMC8607551

[143] ChenB,ZhangC.Clinical and pathological study of SORD-related distal motor neuropathy caused by novel compound heterozygous mutations in a Chinese patient.Clin Neurol Neurosurg2022;213:107118

[144] LaššuthováP,StaněkD.Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients.Sci Rep2021;11:8443 PMCID:PMC8055917